Detalhe da pesquisa
1.
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
Pediatr Blood Cancer
; 64(8)2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28409853
2.
Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling.
Pediatr Hematol Oncol
; 34(6-7): 365-378, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29211600